Date: 2011-07-19
Type of information: Licensing agreement
Compound: Multikine®
Company: CEL-SCI Corporation (USA) Teva Pharmaceutical (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: Licensing
Development
Commercialisation
Distribution
Action mechanism:
Disease: head and neck cancer
Details: CEL-SCI Corporation has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine®. Under the agreement, Teva\'s exclusive license to market and distribute Multikine, the Company\'s investigational Phase III drug for the treatment of head and neck cancer, in Israel and Turkey will be extended to include Croatia and Serbia. Teva is currently funding a part of the global Phase III clinical study at three clinical sites in Israel. Teva will be responsible for the costs of registering and selling the product in Serbia and Croatia and will pay CEL-SCI milestone payments upon approval of Multikine. The parties will share revenue generated from all four countries.
Financial terms:
Latest news:
